A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Active, not recruiting · NCT04644770 · Registry updated 2026-09-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, carcinoma, epithelial neoplasm, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 1 | 2026-09-28 | NCT04644770 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Janssen Research & Development, LLC | 188 |
11 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Case Western Reserve University | Cleveland | United States | 219 |
| City of Hope | Duarte | United States | 238 |
| East Jefferson General Hospital | Metairie | United States | 66 |
| Mayo Clinic Arizona | Phoenix | United States | 55 |
| Mayo Clinic in Florida | Jacksonville | United States | 89 |
| Mayo Clinic Rochester | Rochester | United States | 133 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 1000 |
| Tulane University Hospital & Clinics | New Orleans | United States | 2 |
| University of Chicago | Chicago | United States | 312 |
| University of Utah Huntsman Cancer Institute | Salt Lake City | United States | 15 |
| XCancer Omaha / Urology Cancer Center | Omaha | United States | 7 |